12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Paclical micellular paclitaxel: Interim Phase III data

Interim data from about 400 patients in an ongoing, open-label, European Phase III trial showed that 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle reduced CA 125 to the same level as that of paclitaxel plus carboplatin. Based...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >